Hemolytic anemia
Pathology · Topic 16
Source: NMC CBME Curriculum 2024 · Volume I · Pathology · Topic 16 · combined PDF page 192
Practice questions
- A patient has anemia and a positive direct antiglobulin test (DAT). Which approach best avoids overdiagnosing autoimmune hemolytic anemia?
- A patient has laboratory and clinical evidence of hemolysis, but routine DAT testing is negative. Which conclusion is most appropriate?
- Which statement best describes what the DAT contributes to the evaluation of suspected warm autoimmune hemolytic anemia?
- A DAT is positive in a patient without convincing clinical or laboratory evidence of hemolysis. Which interpretation is most defensible?
- What is the defining antibody pattern of mixed autoimmune hemolytic anemia?
- A patient has evidence of both warm and cold autoantibodies and marked anemia. Which diagnosis best fits this antibody pattern?
- Which statement about the evidence base for mixed AIHA is most accurate?
- In the systematic review of 81 mixed AIHA patients, which underlying condition group was reported as the most frequent etiology?
- Which outcome best reflects the treatment experience reported in the systematic review of mixed AIHA?
- A patient with mixed AIHA has persistent hemolysis despite initial treatment. Which statement is most consistent with the reviewed clinical experience?
- Which mechanism was proposed in the supplied review as one route by which viruses may contribute to AIHA?
- Which set contains only mechanisms that the supplied review proposed for virus-associated AIHA?
- Why does the supplied review recommend vigilance for viral infection in patients receiving AIHA treatment?
- Which statement best characterizes current prevention and management protocols for virus-associated AIHA according to the supplied review?
- In a systematic review of 105 reported COVID-19-associated AIHA cases, which subtype was most frequently reported?
- Which treatment was most commonly used among recovered patients in the systematic review of COVID-19-associated AIHA?
- A review identifies AIHA cases occurring in patients with COVID-19. Which inference is justified by this case-based evidence?
- Which clinical presentation was described as common among patients in the systematic review of COVID-19-associated AIHA?
- Which complication pattern is associated with major ABO-incompatible hematopoietic stem-cell transplantation in the supplied review?
- Which hemolytic complication is described as typical of minor ABO-incompatible HSCT?
- After ABO-mismatched HSCT, delayed hemolysis occurs and the clinical picture does not clearly distinguish whether the responsible alloimmune process is host- or graft-associated. Which statement best reflects the supplied review?
- Which set of management approaches is listed for the clinical spectrum of alloimmune hemolysis after ABO-incompatible HSCT?
- A transplant recipient develops delayed hemolysis after an ABO-incompatible HSCT. Which conclusion is most consistent with the review?
- According to the supplied review, what is a known biological effect of BAFF binding to BAFF-R?
- Which statement about the BAFF pathway in warm AIHA is supported by the supplied review?
- Why is the BAFF/BAFF-R pathway of interest as a potential treatment target in warm AIHA?
- A systematic review of AI-augmented screening for selected hereditary hemolytic anemia carriers reported which pooled diagnostic performance?
- Which limitation did the systematic review identify as important before routine deployment of AI-augmented hereditary hemolytic anemia carrier screening?
- What equity concern did the systematic review report for AI-assisted hereditary hemolytic anemia carrier detection?